Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Published byDamon Mathews Modified over 4 years ago

Similar presentations

Presentation on theme: "Presented By Joshua Richter at 2016 ASCO Annual Meeting"— Presentation transcript:

1 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Updated Data from a Dose Finding Phase II Trial <br />of Single Agent Isatuximab (Anti-CD38 mAb) <br />in Relapsed/Refractory Multiple Myeloma Presented By Joshua Richter at 2016 ASCO Annual Meeting

2 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 2 Presented By Joshua Richter at 2016 ASCO Annual Meeting

3 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 3 Presented By Joshua Richter at 2016 ASCO Annual Meeting

4 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 4 Presented By Joshua Richter at 2016 ASCO Annual Meeting

5 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 5 Presented By Joshua Richter at 2016 ASCO Annual Meeting

6 Presented By Joshua Richter at 2016 ASCO Annual Meeting
<br /> Presented By Joshua Richter at 2016 ASCO Annual Meeting

7 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 7 Presented By Joshua Richter at 2016 ASCO Annual Meeting

8 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 8 Presented By Joshua Richter at 2016 ASCO Annual Meeting

9 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 9 Presented By Joshua Richter at 2016 ASCO Annual Meeting

10 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 10 Presented By Joshua Richter at 2016 ASCO Annual Meeting

11 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 11 Presented By Joshua Richter at 2016 ASCO Annual Meeting

12 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 12 Presented By Joshua Richter at 2016 ASCO Annual Meeting

13 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 13 Presented By Joshua Richter at 2016 ASCO Annual Meeting

14 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Slide 14 Presented By Joshua Richter at 2016 ASCO Annual Meeting

15 Isatuximab Infusion Duration
Presented By Joshua Richter at 2016 ASCO Annual Meeting

16 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Summary Presented By Joshua Richter at 2016 ASCO Annual Meeting

17 Presented By Joshua Richter at 2016 ASCO Annual Meeting
Acknowledgments Presented By Joshua Richter at 2016 ASCO Annual Meeting

Download ppt "Presented By Joshua Richter at 2016 ASCO Annual Meeting"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
Test practice Multiplication. Multiplication 9x2.

Test practice Multiplication. Multiplication 9x2.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Patrick Wen at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
Phase Difference = 0.00. Phase Difference = 0.05.

Phase Difference = Phase Difference = 0.05.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Slide 1 Presented By Edward Neuwelt at 2014 ASCO Annual Meeting.

Slide 1 Presented By Edward Neuwelt at 2014 ASCO Annual Meeting.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Similar presentations

Ads by Google